BNR (Burning Rock) Year-over-year net earnings per share growth for the last 12 months

Graphic logo of Burning Rock Biotech (BNR)

Burning Rock Biotech (BNR) is expanding its liquid biopsy network by implementing DNA sequencing in Chinese clinics for rapid tumor diagnostics. This quarterly earnings per share growth chart illustrates revenue dynamics, where the -100.30 level reflects the current value of the metric. High FDA and NMPA barriers protect the market, while the optimization of logistics routes and reagent inventories eliminates supply chain disruptions.

brbiotech.com (BNR) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/15/2026

Summary analytical data breakdowns for Burning Rock Biotech (BNR)

- market value and analyst target forecast:
Fundamental valuation:Burning Rock Biotech Limited, BNR
Manufactured product of Burning Rock Biotech Ltd

The market values Burning Rock Biotech (BNR) through the lens of scaling molecular profiling within hospitals, which creates a steady stream of oncology diagnostic orders. The quarterly EPS trajectory measures net profit per share dynamics, allowing analysts to isolate random spikes from a sustainable recovery in profitability and confirm the fundamental viability of the business model during its post-crisis recovery.